Introduction
Interleukin (IL)-1 is a physiologically active factor produced and secreted by a variety of cells including those responsible for controlling immunity. Furthermore, it plays an important role in immune reactions, cell damage, and cell-proliferation (1, 2) . IL-1 consists of two molecules, IL-1α and IL-1β, both of which exert similar but not completely overlapping biological functions mediated through the IL-1 type I receptor (IL-1RI). Another IL-1 receptor, the type II receptor (IL-1RII), has also been identified, but this receptor is not considered to be involved in signal transduction, but is rather thought to play a regulatory role as a "decoy". In addition, another member of the IL-1 gene family, IL-1 receptor antagonist (IL-1Ra), binds to IL-1 receptors without exerting agonistic activity. IL-1Ra as well as IL-1RII and the secretory forms of IL-1RI and IL-1RII are considered to negatively regulate IL-1 signaling (3) .
The balance between IL-1 and IL-1Ra has significant effects on host responses to inflammation and infection (4, 5) . In the immune system, IL-1 has many systemic effects in the protection of the body, being involved in fever, the response to stress, and the metabolism of insulin, lipid and bone (6, 7) . Notably, in vascular homeostasis, IL-1 is considered one of the most potent proinflammatory cytokines acting on endothelial cells (ECs) and smooth muscle cells (SMCs) (8) . IL-1 is produced from these cells as well as macrophages (Mφs) and hepatocytes (9, 10) . IL-1 induces the expression of surface leukocyte adhesion molecules in ECs, proliferation of SMCs, and secretion of other cytokines and chemokines from ECs, SMCs, and Mφs (11, 12) . These effects of IL-1 are strongly implicated in cardiovascular diseases (13) (14) (15) . IL-1Ra, one of the negative regulators of IL-1 signaling, plays a role as an anti-inflammatory cytokine, similar to IL-10 and TGF-β, in acute-and chronic-inflammation of the vascular wall (16, 17) . IL1Ra is also produced by ECs and SMCs as well as Mφs for maintaining vascular homeostasis (18, 19) . This re-view, focuses on the effects of IL-1Ra on atherogenesis and cholesterol metabolism.
Structure of Human IL-1 Ra
IL-1Ra was originally discovered as an inhibitor of IL-1 in the urine of patients with fever (20) . A cDNA encoding the secreted form of the molecule was identified in a human monocyte library (21) . Secretory IL-1Ra (sIL-1Ra) is synthesized as a 177-amino acid protein requiring the cleavage of a 25-amino acid leader sequence prior to secretion as a variably glycosylated 152-amino acid protein. A second cDNA coding for an intracellular form of IL-1Ra (icIL-1Ra) was cloned from a different human monocyte library (22) . These two isoforms of IL-1Ra are created by alternative splicing yielding different first exons (23) . The internal splice acceptor site for icIL-1Ra was located within the first exon for sIL-1Ra, near the 3' end of the sequence coding for the signal peptide. icIL1Ra does not have a functional leader sequence and remains in the cytoplasm. The sIL-1Ra protein is produced by many cells that can synthesize IL-1. icIL-1Ra is found constitutively in keratinocytes and other epithelial cells but is also a delayed product of stimulated Mφs (24, 25) . Neutrophils contain only sIL-1Ra mRNA, whereas fibroblasts are capable of producing the mRNA and protein for both IL-1Ra isoforms, when appropriately stimulated (26) .
Function of IL-1 Ra
In spite of extensive studies on IL-1 over the past two decades, the important roles that this cytokine may play in normal biology are unclear (27, 28) . Furthermore, it remains unknown whether the function of IL-1Ra is limited to regulating the agonistic effects of extracellular IL-1 in normal biologic processes or in pathophysiological conditions. Studies on the functional consequences of overexpression or absence of expression of IL-1Ra in transgenic or knockout mice, respectively, may clarify some possible roles of this cytokine in normal biology. This review relates our new findings (obtained from IL1Ra-deficient mice (IL-1Ra -/-)) about the effects of IL-1Ra on arteries and cholesterol metabolism.
IL-1Ra and neointima formation after injury
Neointimal hyperplasia is characterized by the activation, migration, and proliferation of SMCs and is associated with inflammatory mediators such as cytokines. IL-1β is a chemoattractant and mitogen for SMCs (28) that is overexpressed at sites of the active proliferation and migration of this cell type subsequent to injury (29) . Furthermore, a recent report demonstrated that IL-1RI genedeficient mice tended to develop less neointima than wildtype mice (30) . In sum, these previous studies suggested that IL-1 might promote neointimal formation. However, it remained uncertain whether IL-1Ra, the endogenous inhibitor of this central cytokine, could significantly suppress this response in the vasculature. Using IL-1Ra -/-mice (on the C57BL/6J background) and wild-type (IL1Ra +/+ ) mice, we investigated neointimal formation 3 weeks after femoral artery injury induced with an external vascular cuff. The mean intimal thickness and the intima/media ratio of IL-1Ra -/-mice increased by 249% and 257%, respectively, compared with IL-1Ra +/+ mice ( Fig.  1A ) (31) . Control immunostaining for IL-1Ra in injured vessels identified IL-1β and the endogenous inhibitor in the endothelium and inflammatory cells of adventitia in IL-1Ra +/+ mice but not IL-1Ra -/-mice ( Fig. 1B) (31) . These results suggest that IL-1Ra protein prevents inflammation of both the intima and adventitia after cuff injury. Indeed, IL-1Ra -/-mice showed an increase in the proliferating cell nuclear antigen (PCNA) index of the intima and adventitia after injury. Within the adventitia, proliferating monocytes and macrophages comprised the majority of PCNA-positive cells. Recent studies have shown that adventitial passive fibroblasts can become active myofibroblasts under conditions of adventitial inflammation (32, 33) . On the other hand, SMCs were the predominant proliferating cell type in the intima (31) . IL-1 itself is a mitogen for SMCs (28) , and furthermore, a recent study showed that vascular intima formation after mechanical injury mainly involves inflammatory cells that originate from the bone marrow (34) . Our study demonstrated definitively that a deficiency of endogenous IL1Ra promotes neointimal formation, revealing a crucial role for this protein in hyperplastic responses of the vasculature. Our results may be compatible with the report that p80 IL-1 type I receptor knockout mice tended to develop a smaller (7-fold) neointimal area induced by low shear stress compared to wild-type controls (30) . This report demonstrated that IL-1 modulates low shear stress-induced neointimal formation, thus providing a direct proinflammatory cytokine signaling link between biomechanical forces to a vessel wall and the remodeling response of the artery. They also concluded that specific anti-IL-1 therapy may lessen neointimal formation.
IL-1Ra and atherogenesis
Atherogenesis is a complex process in which the activation of ECs and SMCs appears to be a central theme (8) . IL-1 is produced by these cells as well as Mφs and hepatocytes (9, 10) . Furthermore, stimulation and activation of ECs and SMCs by IL-1 causes a wide range of inflammatory processes within the atheroma, such as the enhanced expression of leukocyte adhesion molecules (9, 12) , clotting factors and inhibitors of fibrinolysis (11) , and chemokines (28) , as well as increased proliferation of SMCs (8, 15) , suggesting a central role for IL-1 in the development of atherosclerosis. The activity of IL-1 is counter-regulated by its endogenous inhibitor IL-1Ra (15, 27) and a previous report showed that IL-1Ra is expressed in ECs and atherosclerotic lesions (18) . Treatment with recombinant IL-1Ra proved an effective therapy for atherosclerosis in apoE -/-mice (35) . Furthermore, low density lipoprotein receptor-deficient (LDLR -/-) mice crossed with transgenic mice expressing high levels of murine sIL-1Ra were also partially protected compared to their non-transgenic controls. In contrast, LDLR -/-IL1Ra -/-mice had a tendency to develop foam cell lesions on a diet rich in cholesterol and cholate (36) . Moreover, in humans IL-1Ra gene polymorphism is significantly associated with coronary artery disease (37) . These findings suggest that endogenous IL-1Ra may suppress atherosclerosis. To directly answer the question of whether a deficiency of IL-1Ra promotes the development of ath- (38) . Following 32 weeks, the differences in lesion size between these mice failed to achieve statistical significance (38) . However, immunostaining demonstrated an 86% increase in the MOMA-2-stained area in IL1Ra +/-/ apoE -/-mice ( Fig. 2A) . In addition, α-actin stain- -/-(right) mice (day 7). Boxed areas are enlarged at the bottom of the panels. IL-1Ra protein is present in both the endothelium and some inflammatory cells (arrows) in IL1Ra +/+ mice. Original magnification X 100 (upper panels) and X150 (bottom panels). ing in these lesions was significantly decreased (-15%) compared to that in IL-1Ra +/+ / apoE -/-mice ( Fig. 2B) (38) . Our real-time polymerase chain reaction (RT-PCR) analysis revealed that deletion of IL-1Ra increases the mRNA expression of the adhesion molecules vascular cell adhesion molecule (VCAM)-1 and intercellular adhesion molecule (ICAM)-1 in the aorta, and enhances mRNA levels of monocyte chemoattractant protein (MCP)-1 (38) . These changes may contribute to the enhanced accumulation of Mφs in advanced plaques. Interestingly, IL-1β -/-/ apoE -/-mice showed opposite results, thus demonstrating that the size of atherosclerotic lesions at the aortic sinus in IL-1β -/-/apoE -/-mice at 12 and 24 weeks of age showed a significant decrease of 30% compared with that in IL-1β +/+ /apoE -/-mice, and the mRNA levels of VCAM-1 and MCP-1 in the IL-1β -/-/apoE -/-aorta were significantly reduced compared with those in the IL-1β +/+ /apoE -/-mice (39). They suggested that IL-1β exerts an atherogenic action by enhancing the expression of VCAM-1 and MCP-1 in the aorta. This report may support our results. Taken together, these findings suggest an important role for IL-1Ra in suppressing the development of lesions early during atherogenesis and furthermore, implicate it in the modulation of plaque composition.
IL-1Ra and cholesterol metabolism during chronic inflammation
Infection and inflammation induce an acute-phase response (APR) (40) , leading to multiple alterations in lipid and lipoprotein metabolism (41) . Serum triglyceride (TG) levels are increased by multiple cytokines, including IL-1, IL-2, IL-6 and tumor necrosis factor (42) (43) (44) (45) (46) (47) (48) , because of increased secretin of very low density lipoprotein (VLDL) as a result of adipose tissue lipolysis (49) (50) (51) . With more severe inflammation, the clearance of VLDL decreases secondary to decreased lipoprotein lipase and apolipoprotein E in VLDL (52) (53) (54) . LPS and cytokines reduce total serum cholesterol levels in primates, whereas in rodents they increase cholesterol levels by stimulating de novo cholesterol synthesis (55, 56) , decreasing lipoprotein clearance (57) , limiting the conversion of cholesterol to bile acids (58, 59) , and decreasing the secretion of cholesterol into the bile (60) (61) (62) (63) . Many of the changes in lipoproteins during inflammation help to protect the host from harmful effects of the stimuli. However, if prolonged, these changes in the structure and function of lipoproteins will contribute to atherogenesis. Of note, inflammatory cytokines are increased and play a pathogenic role in a variety of very common disorders, such as diabetes, obesity, metabolic syndrome, and atherosclerosis (64) (65) (66) (67) (68) . Many of these disorders display abnormalities in lipid metabolism that are similar to those that occur during infection and inflammation. However, the effect of chronic inflammation on lipid metabolism has been unclear. Furthermore, there is no report that shows the role of IL-1Ra in the metabolism of cholesterol under chronic inflammatory conditions.
To elucidate the role of IL-1Ra, we fed an atherogenic diet (with cholate) to both IL-1Ra -/-and IL-1Ra +/+ mice. IL-1Ra -/-mice developed severe fatty liver after 20 weeks compared to IL-1Ra +/+ mice (Fig. 3A) (69) . Histological examination revealed an increase in the number and size of intracellular vacuoles, portal fibrosis, and collagen deposition as well as lobular and portal inflammation in livers of IL-1Ra -/-mice. Expectedly, the plasma lipid profile became more proatherogenic with increased total cholesterol levels (942 ± 160 mg/dl versus 240 ± 13 mg/ dl, n = 5; p < 0.01), higher apoB-containing lipoprotein levels (699 ± 126 mg/dl versus 192 ± 36 mg/dl; p < 0.01), and decreased HDL levels (31 ± 10 mg/dl versus 54 ± 3 mg/dl; p < 0.05) in IL-1Ra -/-mice compared to IL-1Ra +/+ mice after 20 weeks on the atherogenic diet (Fig. 3B ).
Real-time PCR analysis revealed that the decreasein the IL-1Ra mRNA level was accompanied by a increase in the levels of IL-1β (P < 0.001), TGF-β (P < 0.01) and CD68 mRNA (P < 0.001) in the IL-1Ra -/-liver compared to the WT liver. Furthermore, IL-1Ra -/-mice failed to express mRNA of cholesterol 7α-hydroxylase (CYP7A1) (p < 0.05), the rate-limiting enzyme in bile acid synthesis, with upregulation of small heterodimer partner 1 (SHP) mRNA expression (p < 0.001) following 4 weeks on the atherogenic diet (69) . Indeed, IL-1Ra -/-mice showed markedly decreased bile acid excretion, which is promoted in WT mice to maintain cholesterol levels while feeding on an atherogenic diet. Our results show that both bile acid and high cytokine levels in IL-1Ra -/-mice reduced the mRNA expression of CYP7A1 with a upregulation of SHP mRNA expression. We summarize the mechanism of these changes in Fig. 4 . Several previous reports demonstrated that administration of cholic acid in mice induced SHP gene expression (70, 71) and SHP reduces CYP7A1 expression (72) . Increased concentrations of bile acids in the liver could, in turn, induce inflammation and the lack of IL-1Ra, an anti-inflammatory cytokine, might worsen the inflammation in IL-1Ra -/-liver. Furthermore, large amounts of cytokines produced in response to severe inflammation in IL-1Ra -/-mice could also play an important role in the up-regulation of SHP expression. Cytokine-dependent signaling leads to the activation of c-Jun N-terminal kinase (JNK) and other mitogen-activated protein kinases (73, 74) . Recently, Gupta et al. showed that c-Jun activated by cytokines induces SHP-1 promoter activity and mutations in the AP-1 binding site abolished bile acid responsiveness of the rat SHP promoter (75) . Thus, they suggested that activation of the JNK/c-jun pathway is needed for the induction of SHP by bile acids. Furthermore, Miyake et al. demonstrated that bile acid-induced expression of cytokines (such as TNF-α and IL-1) by macrophages correlates with repression of hepatic CYP7A1 (76) , further supporting our findings. Thus, atherogenic diet-induced inflammation with both a high IL-1 level and deficiency of IL-1Ra caused an up-regulation of SHP expression and, in turn, downregulation of CYP7A1. The suppression of CYP7A1 causes more cholesterol to accumulate in IL-1Ra -/-mice. We conclude that the significant increase in SHP expression in IL-1Ra -/-liver is an indirect effect of loss of IL1Ra, but IL-1Ra plays an important role in maintaining cholesterol homeostasis under conditions of cholic acidinduced inflammation. 
Conclusion
During the last five years, transgenic and gene knockout studies in murine models of vascular disease have established IL-1 and IL-1Ra as pivotal players in the regulation of vascular cell functions and cholesterol metabolism. Although genetic differences between mouse and man preclude a direct translation of these findings to human disease, these studies have identified several pathways whose perturbation has the potential to significantly shift the balance between disease progression and retardation. An important goal of future studies will be moredetailed investigations of the particular genes and proand anti-inflammatory pathways regulated by different cytokines in atherogenesis and cholesterol metabolism. This challenge could lead to promising novel therapeutic targets for anti-inflammatory therapies, potentially even harnessing some of the sophisticated regulatory systems designed to normally limit the inflammatory response.
